Welcome to our dedicated page for Biomarin Pharmaceutical news (Ticker: BMRN), a resource for investors and traders seeking the latest updates and insights on Biomarin Pharmaceutical stock.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a global rare disease biotechnology company focused on medicines for genetically defined conditions. This news page aggregates company announcements, press releases and event updates so readers can follow how BioMarin’s strategy, pipeline and commercial portfolio evolve over time.
Recent communications from BioMarin highlight its emphasis on Enzyme Therapies and Skeletal Conditions business units, as well as its work with ROCTAVIAN, a gene therapy for hemophilia A. The company issues news on topics such as financial results, long-term guidance, corporate strategy, business development transactions, clinical data presentations and regulatory milestones for its therapies.
Examples of news themes include updates on VOXZOGO in achondroplasia and other skeletal conditions, progress with PALYNZIQ in phenylketonuria, development of BMN 401 for ENPP1 deficiency and other pipeline programs in rare genetic diseases. BioMarin also reports on strategic partnerships, such as digital and data collaborations, and on planned acquisitions intended to expand and diversify its rare disease portfolio.
Investors and followers of BMRN can use this page to review earnings announcements, conference presentations, investor day materials and product-specific updates released through newswires. By checking this feed regularly, readers can see how BioMarin describes its growth priorities, clinical milestones and capital allocation decisions across its rare disease franchises.
Freddie Mac (OTCQB: FMCC) reported 2025 multifamily production of $77.6 billion, a 17% increase versus 2024, supporting over 577,000 affordable rental units nationwide. The total includes $1.2 billion in LIHTC equity, $1.1 billion in workforce housing preservation loans, and $2.4 billion in forward conversions.
Freddie Mac said it set records in forward commitments and long-term financing, with $2.0 billion in new long-term funding (+42%) and Structured Products totaling $2.5 billion (including $2.2 billion of Q-Deals). The company reported 66% of 2025 volume met its mission-driven affordable housing goal, exceeding the 50% target.
BioMarin (NASDAQ: BMRN) appointed Arpit Davé as Executive Vice President, Chief Digital and Information Officer, effective Jan 12, 2026. Mr. Davé will report to CEO Alexander Hardy and join the BioMarin Leadership Team.
He will lead enterprise technology strategy, data science and digital transformation to support R&D, manufacturing and commercial operations. Mr. Davé brings more than 20 years of IT and AI experience in biopharma, including 7.5 years as a technology executive at Amgen and prior leadership roles at Bristol Myers Squibb and Merck. He holds an M.S. in Industrial Engineering from the University of Texas and a B.S. in Mechanical Engineering from S.P. University.
BioMarin (NASDAQ: BMRN) announced that Alexander Hardy, President and CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 11:15 am PT / 2:15 pm ET in San Francisco.
The company plans to announce certain preliminary financial results for the year ended December 31, 2025 during the presentation. An audio webcast will be available live and an archived version will be posted on the company's investor website for a limited time.
BioMarin (NASDAQ: BMRN) and Veeva Systems (NYSE: VEEV) announced a long-term enterprise agreement on January 8, 2026 to expand their existing relationship.
The partnership aims to increase speed, agility and operational efficiency in developing and commercializing therapies by further leveraging and providing strategic input into Veeva's software, data, services, and consulting products, and to optimize the healthcare professional and patient experience. Company leaders highlighted the collaboration's role in accelerating access to transformative medicines globally.
BioMarin (Nasdaq: BMRN) agreed to acquire Amicus Therapeutics for $14.50 per share, valuing the deal at approximately $4.8 billion. The transaction, approved by both boards, is expected to close in Q2 2026 subject to customary approvals. The deal adds marketed therapies Galafold and Pombiliti + Opfolda that generated $599 million in net product revenue over the past four quarters and resolves U.S. Galafold patent litigation with U.S. exclusivity expected through Jan 2037. BioMarin expects the acquisition to be accretive to Non-GAAP diluted EPS within 12 months and substantially accretive in 2027 and plans to finance with cash plus about $3.7 billion of debt.
BioMarin (NASDAQ: BMRN) said its management team will present at the Jefferies Global Healthcare Conference on Tuesday, November 18, 2025 at 10:30 AM GMT in London, England. An audio webcast will be available live and an archived version of the remarks will be posted on the company investor website for a limited time.
Investors can access the live webcast and archive at https://investors.biomarin.com/.
BioMarin (Nasdaq: BMRN) announced the FDA has accepted for Priority Review its supplemental biologics license application to expand PALYNZIQ (pegvaliase-pqpz) for adolescents aged 12–17 with phenylketonuria (PKU).
The sBLA is based on positive Phase 3 PEGASUS results showing statistically significant reductions in blood phenylalanine (Phe) versus diet alone. The FDA set a PDUFA target action date of Feb. 28, 2026. Data were presented at the 15th ICIEM in Kyoto, and BioMarin plans to seek a similar label expansion with the European Medicines Agency. PALYNZIQ is currently the first and only enzyme substitution therapy approved for adults with PKU.
BioMarin (NASDAQ: BMRN) reported Q3 2025 results and a corporate update on October 27, 2025. Total revenues were $776M (+4% vs Q3 2024) and YTD revenues reached $2,347M (+11% Y/Y). Year-to-date VOXZOGO revenue rose 24% Y/Y and Q3 VOXZOGO sales were $218M; PALYNZIQ grew 20% in Q3. GAAP net loss was $(31)M in Q3, driven primarily by a $221M acquired IPR&D charge from the Inozyme acquisition. Non-GAAP income fell to $22M in Q3 from $178M a year earlier. Cash and investments were about $1.99B and operating cash flow was $369M in Q3 ($728M YTD). The company reaffirmed VOXZOGO full-year guidance ($900M–$935M) and updated 2025 guidance, raising mid-point revenue while lowering Non-GAAP EPS and margin guidance to reflect the IPR&D charge. BioMarin plans to pursue options to divest ROCTAVIAN.
BioMarin (NASDAQ: BMRN) announced a conference call and webcast with Alexander Hardy, president and CEO, on Monday, October 27, 2025 at 4:30 p.m. ET to discuss third quarter 2025 financial results and provide a general business update.
Dial-in numbers are provided for U.S./Canada and international participants, and a live audio webcast will be available via the investor site at https://investors.biomarin.com/. A replay will be archived on the site for one week following the call.
BioMarin Pharmaceutical (Nasdaq: BMRN) presented new data from 14 studies at the ASBMR 2025 Annual Meeting, highlighting significant advances in bone health treatments. The key findings focus on VOXZOGO® (vosoritide) treatment outcomes in children with achondroplasia.
The Phase 2 CANOPY study demonstrated that children receiving VOXZOGO showed improved spinal morphology, with 57% experiencing reduced thoracolumbar kyphosis compared to 33% in the placebo group. Additionally, Phase 3 data revealed substantial growth benefits in post-puberty patients, with treated young men gaining 7.55 cm more and young women gaining 8.07 cm more in height compared to untreated individuals.
The company also presented research on ENPP1 deficiency, advancing BMN 401 as a potential first-in-disease enzyme therapy, with pivotal data expected in early 2026 and potential launch in 2027.
FAQ
What is the current stock price of Biomarin Pharmaceutical (BMRN)?
What is the market cap of Biomarin Pharmaceutical (BMRN)?
